Dana Mitchell, MD
Nephrology · Houston, TXNPI 1659308450
Payments from drug & device makers
Across 809 payments — averaging $568.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$222K
- Amgen$96K
- AstraZeneca$78K
- Mallinckrodt Hospital Products Inc.$40K
- Mallinckrodt Enterprises LLC$13K
- GSK$6K
- plus $3K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 133 | $222,464 |
| Amgen(2 entities) | 215 | $96,156 |
| AstraZeneca(2 entities) | 182 | $78,490 |
| Mallinckrodt Hospital Products Inc. | 80 | $40,152 |
| Mallinckrodt Enterprises LLC | 22 | $13,220 |
| GSK | 22 | $6,440 |
| Akebia Therapeutics Inc | 44 | $705 |
| Otsuka America Pharmaceutical, Inc. | 17 | $355 |
| Vifor Pharma, Inc. | 18 | $319 |
| OPKO Pharmaceuticals, LLC | 20 | $314 |
| Calliditas Therapeutics US Inc. | 5 | $226 |
| Abbott | 4 | $200 |
| Boehringer Ingelheim | 3 | $157 |
| Aurinia Pharma U.S., Inc. | 7 | $127 |
| Travere Therapeutics, Inc. | 6 | $121 |
| Medtronic | 1 | $106 |
| Novartis | 4 | $89 |
| Fresenius USA Marketing, Inc. | 5 | $82 |
| Novo Nordisk | 4 | $69 |
| Cordis US CORP. | 1 | $68 |
| Ardelyx, Inc. | 2 | $56 |
| ANI Pharmaceuticals, Inc. | 2 | $41 |
| Cormedix Inc. | 2 | $38 |
| Sanofi | 2 | $37 |
| Asahi Intecc USA, Inc. | 1 | $36 |
| Pharmacosmos Therapeutics Inc. | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $28 |
| Merck | 1 | $26 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Boston Scientific | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Amicus Therapeutics, Inc. | 1 | $17 |
How this compares
$460,231 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Houston
- Sreedhar MandayamHouston$7M
- Marializa BernardoHouston$4.2M
- Stephen FademHouston$2.4M
- Biruh WorkenehHouston$1.8M
- Rahul PandeyHouston$1.6M
- Christopher KwohHouston$928K
- George NassarHouston$772K
- June YaoHouston$651K
- Maher BisharaHouston$489K
- Wolfgang WinkelmayerHouston$462K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.